<DOC>
	<DOC>NCT01812148</DOC>
	<brief_summary>Review of the investigators hospital experience in cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) for peritoneal mesotheliomas, using Oxaliplatin as intraperitoneal chemotherapeutic agent.</brief_summary>
	<brief_title>Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC)</brief_title>
	<detailed_description>Observation of primary outcome: - Overall Survival - Disease-free survival Influencing factors that will be observe: - Sex - Blood loss - Time of surgery - Number of resection and anastomosis - Peritoneal Index (PI score) - Cytoreductibility (CCR score)</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Peritoneal mesothelioma Non resectable disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Peritoneal Mesotheliomas</keyword>
	<keyword>hyperthermic intra-peritoneal chemotherapy (HIPEC)</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Cytoreductive surgery</keyword>
	<keyword>Oxaliplatin HIPEC</keyword>
</DOC>